Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a cytological or histological diagnosis of adenocarcinoma arising in the pancreas. Diagnosis from metastatic sampling is acceptable.~* Disease must be measured radiologically.~* Failed initial therapy or ineligible for definitive curative therapy.~* If prior treatment included radiation therapy, recurrent disease must be outside of the targeted volume.~* Age ≥ 18 years~* ECOG performance status 0-2 (Karnofsky \> 50%, see Appendix A).~* Patients must have normal organ and marrow function as defined below:~  * leukocytes ≥ 3,000/mm3~ * absolute neutrophil count ≥ 1,500/mm3~ * platelets ≥ 100,000/mm3~ * total bilirubin \< 2x institutional upper limit of normal~ * AST(SGOT) \< 3x institutional upper limit of normal OR \< 5x institutional upper limit of normal for patients presenting with liver metastases~ * ALT (SGPT) \< 3x institutional upper limit of normal OR \< 5x institutional upper limit of normal for patients presenting with liver metastases~ * PT/INR within normal institutional limits, unless patient is on warfarin or other antithrombotic agents~ * creatinine \< 1.5 X institutional upper limit of normal OR creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.~ * Not pregnant. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.~ * Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~* Prior chemotherapy to treat metastatic disease.~* Adjuvant therapy (including radiation therapy) within 4 calendar weeks.~* Unresolved toxicities from prior therapy for the malignancy.~* G6PD (glucose-6-phosphate dehydrogenase) deficiency.~* Second malignancy other than non-melanoma skin cancers within the past 5 years.~* Excess consumption of alcohol where an excess of alcohol is defined as more than four of any one of the following per day: 30 mL distilled spirits, 340 mL beer, or 120 mL wine.~* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness/social situations, or any other condition that would limit compliance with study requirements as determined by study team members.~* Pregnant or lactating women: The risks of chemotherapy to a fetus/infant are well documented.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine with escalating IV ascorbate (Type: EXPERIMENTAL): Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off.~Ascorbate (vitamin C) given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbate / infusion for two infusions. Doses are then escalated in 25 gram increments until therapeutic window is achieved (350 mg/dL or above). Dose is then held at that level for the full cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues